12235University of Miami Miller School of Medicine, Miami, FL, USA.
Sylvester Comprehensive Cancer Center, 12235University of Miami Miller School of Medicine, Miami, FL, USA.
Int J Surg Pathol. 2021 Sep;29(6):600-605. doi: 10.1177/1066896921991588. Epub 2021 Mar 25.
Cathepsin K is overexpressed in several tumors associated with microphthalmia transcription factor (MiTF) family or mechanistic target of rapamycin (mTOR) upregulation. Among renal neoplasms, MiTF translocation renal cell carcinoma (RCC), perivascular epithelioid cell neoplasms (PEComa), and eosinophilic solid and cystic RCC have demonstrated Cathepsin K immunoreactivity. In this study, we demonstrate a uniform Cathepsin K expression in oncocytoma, chromophobe RCC (CHRCC), and distal tubules. We stained 13 oncocytomas, 13 CHRCC, 14 clear cell RCC (CCRCC), 9 papillary RCC (PRCC), 9 PEComas, and 5 MiTF RCC. Additionally, we assessed immunoreactivity for Cathepsin K in non-neoplastic renal parenchyma. Immunolabeling was performed on regularly charged slides from formalin-fixed paraffin-embedded tissue with monoclonal anti-rabbit antibodies to human Cathepsin K (clone EPR19992, Abcam). All oncocytomas demonstrated diffuse strong cytoplasmic immunolabeling. CHRCC demonstrated uniform less intense immunolabeling in all cases with membranous accentuation. The assessment of the non-neoplastic renal parenchyma in all cases showed strong cytoplasmic immunoreaction in distal tubules and proximal tubules stained faintly. Mesangial cells were not immunoreactive. All MiTF RCC and PEComas were immunoreactive for Cathepsin K, whereas CCRCC and PRCC were negative in all cases. In this study, we expand the spectrum of renal neoplasms reactive with a particular clone of Cathepsin K (EPR19992). Distal tubules are strongly immunoreactive for Cathepsin K. Our conclusions need to be taken into consideration when differential diagnosis includes MiTF RCC or PEComa and this Cathepsin K clone is included in the immunohistochemical panel. This newer antibody clone was not tested in prior publications, potentially explaining the difference in conclusions.
组织蛋白酶 K 在几种与小眼转录因子 (MiTF) 家族或雷帕霉素靶蛋白 (mTOR) 上调相关的肿瘤中过度表达。在肾肿瘤中,MiTF 易位肾细胞癌 (RCC)、血管周上皮样细胞肿瘤 (PEComa) 和嗜酸性实性和囊性 RCC 显示组织蛋白酶 K 免疫反应性。在这项研究中,我们证明了嗜酸细胞瘤、嫌色细胞肾细胞癌 (CHRCC) 和远曲小管中均有统一的组织蛋白酶 K 表达。我们对 13 例嗜酸细胞瘤、13 例 CHRCC、14 例透明细胞肾细胞癌 (CCRCC)、9 例乳头状肾细胞癌 (PRCC)、9 例 PEComa 和 5 例 MiTF RCC 进行了染色。此外,我们还评估了非肿瘤性肾实质中组织蛋白酶 K 的免疫反应性。免疫标记是在常规固定石蜡包埋组织的带电幻灯片上进行的,使用单克隆抗兔抗人组织蛋白酶 K(克隆 EPR19992,Abcam)。所有嗜酸细胞瘤均表现为弥漫性强细胞质免疫标记。CHRCC 在所有病例中均表现为均匀较弱的免疫标记,伴有膜强调。所有病例的非肿瘤性肾实质评估均显示远曲小管和近端小管染色微弱的细胞质免疫反应。系膜细胞无免疫反应性。所有 MiTF RCC 和 PEComa 对组织蛋白酶 K 均有免疫反应性,而 CCRCC 和 PRCC 在所有病例中均为阴性。在这项研究中,我们扩展了对特定组织蛋白酶 K(EPR19992)克隆有反应的肾肿瘤谱。远曲小管对组织蛋白酶 K 呈强免疫反应性。当鉴别诊断包括 MiTF RCC 或 PEComa 且该组织蛋白酶 K 克隆包含在免疫组化面板中时,我们的结论需要考虑在内。这种新的抗体克隆在之前的出版物中未进行测试,这可能解释了结论的差异。